Navigation Links
Stemedica Announces the Appointment of Dr. Csar Amescua Garcia as Medical and Regulatory Affairs Director – Latin America
Date:6/24/2010

Dr. Amescua will be responsible for liaison with regulatory agencies in Latin America regarding approvals of Stemedica’s allogeneic adult stem cell products for use in clinical (human) trials which follow the criteria required by the FDA in the United States.

(PRWEB) June 24, 2010 -- Stemedica Cell Technologies, Inc., a leader in allogeneic adult stem cell manufacturing, research and development announced today the appointment of César Amescua, MD as Medical and Regulatory Affairs Director for Latin America. Dr. Amescua will be responsible for liaison with regulatory agencies in Latin America regarding approvals of Stemedica’s stem cell products for use in clinical (human) trials which follow the criteria required by the FDA in the United States.

Dr. Amescua is a member of the senior medical leadership at Groupo Angeles, one of the largest health care providers in all of Latin America. He is also President of the Mexican Association for the Study and Treatment of Pain. "I am excited and proud to be working with Stemedica. The company is a leader in the stem cell manufacturing field, and is bringing innovative technology to countries around the world. Latin America holds great promise for Stemedica’s products and services as Latin America seeks to address the epidemic of degenerative diseases and conditions that are bankrupting health care systems around the world."

Dr. Lev Verkh, Stemedica’s Chief Regulatory and Clinical Development Officer, commented, "We’re pleased and delighted to have Dr. Amescua joining our team at Stemedica. His medical leadership and his regulatory expertise will be critical in establishing clinical trials throughout Latin America using Stemedica stem
'/>"/>

Source: PRWeb
Copyright©2010 Vocus, Inc.
All rights reserved  

Page: 1 2

Related biology technology :

1. Stemedica Announces the Appointment of Dr. Lev Verkh as Chief Regulatory and Clinical Development Officer
2. Stemedica Completes Meeting with the FDA
3. United States Patent and Trademark Office Publishes Stemedica's Patent Application for the Treatment of Diabetic Retinopathy
4. The Jordanian Stem Cell Company Acquires Stem Cell Technology From Stemedica International S.A. - First Clinical Trail Anticipated To Begin Early 2010
5. Stemedica Achieves Major Milestone - Company Receives License to Manufacture Clinical Grade Stem Cells
6. Stemedica Selected By World Stem Cell Summit To Present Scientific Discoveries
7. Stemedica Requests Pre-IND Meeting With FDA
8. Stemedica Signs Scientific Advisory Board Agreement with Leading Pediatric Burn & Wound Care Researcher
9. Renowned Stem Cell Researcher Files Study Results With Stemedica
10. CIRM Completes Briefing Visit to Stemedica Cell Technologies
11. Stemedica Announces the Appointment of Dr. Michael Bayer as Director, Medical Services
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Stemedica Announces the Appointment of Dr. Csar Amescua Garcia as Medical and Regulatory Affairs Director – Latin America 
(Date:12/19/2014)... , Dec. 18, 2014   ISN has ... Safety Performance Indicators publication series. With data ... activity reported in 2013 within its online contractor management ... safety key performance indicator (KPI) statistics. ... U.S. publication is available in two industry ...
(Date:12/17/2014)... New York, NY (PRWEB) December 16, 2014 ... undergone significant changes since 2013, which is why IBISWorld ... one, this industry continues to benefit from an intensified ... 2014, the proposal for new emission standards for power ... affected industry operators. According to IBISWorld Industry Analyst Sarah ...
(Date:12/17/2014)... USA (PRWEB) December 16, 2014 ... manager at Philipps- Universität Marburg’s Department of Physics, ... photonics, in the newly released SPIE Women ... never be too shy to ask questions.” , ... technology, engineering, and mathematics) occupations ranging from university ...
(Date:12/17/2014)... (PRWEB) December 17, 2014 Ipsen ... IPN; ADR: IPSEY), today announced that ... to as Somatuline®) was approved by the U.S. ... of gastroenteropancreatic neuroendocrine tumors (GEP-NETs) in adult patients ... or metastatic disease to improve progression-free survival (PFS). ...
Breaking Biology Technology:ISN Releases Third Edition of US Contractor Health & Safety Performance Indicators Publication Series 2ISN Releases Third Edition of US Contractor Health & Safety Performance Indicators Publication Series 3Activated Carbon Manufacturing in the US Industry Market Research Report Has Been Updated from IBISWorld 2Activated Carbon Manufacturing in the US Industry Market Research Report Has Been Updated from IBISWorld 3Network, Multitask, Persevere: SPIE Women in Optics Planner Subjects Share from Experience 2Network, Multitask, Persevere: SPIE Women in Optics Planner Subjects Share from Experience 3Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 2Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 3Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 4Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 5Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 6Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 7Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 8
... 8 SuperGen, Inc.,(Nasdaq: SUPG ), a ... commercialization of therapies for solid tumors and,hematological malignancies, ... Michael V. McCullar, Ph.D., Vice President of Drug,Discovery ... 5th,Annual Investor Summit on Monday, September 15, 2008 ...
... (Nasdaq: HGSI ) announced today that its presentation ... will be webcast and,may be accessed at http://www.hgsi.com ... member of Human Genome Sciences, senior management team will ... 10:15 am Eastern,Time., Investors interested in listening to ...
... Presented at the 7th International ... Symposium on Uveitis in Germany, ... antibody fragment therapeutics, today announced that the,company has successfully completed ... ESBA105, in ophthalmic indications. In,April 2008, ESBATech initiated the Phase ...
Cached Biology Technology:SuperGen to Present at Merriman 5th Annual Investor Summit on September 15, 2008 2ESBATech Announces Successful Completion of Phase I Clinical Study for Lead Antibody Fragment in Ophthalmic Indications 2
(Date:11/18/2014)... , Nov. 18, 2014   EyeLock ... authentication solutions, and MorphoTrust USA (Safran), ... services, today announced a strategic partnership to offer ... motor vehicle administration (MVA), airport screening and financial ... identity-related solutions, MorphoTrust serves consumers through a nationwide ...
(Date:11/12/2014)... BEACH GARDENS, Fla. , Nov. 12, 2014 /PRNewswire/ ... solutions, announced today that its U.are.U ® fingerprint ... retail bakery chain in Central Mexico ... in June 2014 to eliminate payroll issues caused by ... Prior to installing the U.are.U fingerprint readers, Montparnasse relied ...
(Date:11/10/2014)... shelves in early 2010, and people have used them ... be tossed into a washing machine without ever having ... though, has come with risks for young children. , ... found that from 2012 through 2013, U.S. poison control ... years of age swallowing, inhaling, or otherwise being exposed ...
Breaking Biology News(10 mins):EyeLock, MorphoTrust Form Strategic Partnership to Pursue Commercial Enterprise Deployments 2EyeLock, MorphoTrust Form Strategic Partnership to Pursue Commercial Enterprise Deployments 3Montparnasse Pasteleria Achieves Time and Attendance Transparency with Crossmatch U.are.U Fingerprint Readers 2Study finds laundry detergent pods, serious poisoning risk for children 2
... capacity to buffer against climate change? As one ... takes up roughly one-third of all human carbon emissions, ... But whether the ocean can continue mopping up ... in the air. Previous studies on the topic have ...
... of Houston researcher is an author on a landmark ... form of ovarian cancer that is published in the ... Ovarian cancer is the fifth-leading cause of cancer death ... study, which was conducted by The Cancer Genome Atlas ...
... compounds that can be highly contaminant. They are found, ... pharmaceutical industries and in waters polluted by ships, fuel. ... the impact of PAHs on a number of media, ... up the methodology, prepared it for the pertinent circumstances ...
Cached Biology News:Climate change reducing ocean's carbon dioxide uptake 2Climate change reducing ocean's carbon dioxide uptake 3University of Houston researcher an author of multi-institutional genetic study of ovarian cancer 2University of Houston researcher an author of multi-institutional genetic study of ovarian cancer 3Determining pollution level of a medium without wasting tools, time or solvents possible 2Determining pollution level of a medium without wasting tools, time or solvents possible 3
... contains 4 deuterium atoms at the 9, 10, ... use as an internal standard for the quantification ... is produced by incubation of linoleic acid with ... to inhibit the adhesion of tumor cells to ...
...
...
Immunogen: Peptide corresponding to amino acid residues from the N-terminal region of human thyroid hormone receptor, alpha1/alpha2-isotype. Storage: -20 C, Avoid Freeze/Thaw Cycles...
Biology Products: